Compare Stocks: PRQR, FTH, NVCT, and PHAR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTH Sensei Biotherapeutics	$25.61 +2.8%	$31.85	$7.45 ▼ $42.14	$643.94M	-0.29	454,958 shs	346,317 shs
NVCT Nuvectis Pharma	$20.13 -0.8%	$21.84	$5.55 ▼ $29.27	$662.35M	-0.24	214,108 shs	179,391 shs
PHAR Pharming Group	$9.53 -1.2%	$10.96	$9.44 ▼ $21.34	$683.01M	-0.05	35,963 shs	5,117 shs
PRQR ProQR Therapeutics	$1.57 -3.7%	$1.93	$1.33 ▼ $3.10	$171.74M	0.2	654,103 shs	1.16 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTH Sensei Biotherapeutics	+2.77%	-9.41%	-34.67%	-29.18%	+2,560,999,900.00%
NVCT Nuvectis Pharma	-0.79%	-2.85%	-16.09%	+9.70%	+223.11%
PHAR Pharming Group	-1.24%	-4.22%	-17.13%	-31.24%	-35.46%
PRQR ProQR Therapeutics	-3.68%	-3.68%	-23.41%	-9.25%	-33.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTH Sensei Biotherapeutics	$25.61 +2.8%	$31.85	$7.45 ▼ $42.14	$643.94M	-0.29	454,958 shs	346,317 shs
NVCT Nuvectis Pharma	$20.13 -0.8%	$21.84	$5.55 ▼ $29.27	$662.35M	-0.24	214,108 shs	179,391 shs
PHAR Pharming Group	$9.53 -1.2%	$10.96	$9.44 ▼ $21.34	$683.01M	-0.05	35,963 shs	5,117 shs
PRQR ProQR Therapeutics	$1.57 -3.7%	$1.93	$1.33 ▼ $3.10	$171.74M	0.2	654,103 shs	1.16 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTH Sensei Biotherapeutics	+2.77%	-9.41%	-34.67%	-29.18%	+2,560,999,900.00%
NVCT Nuvectis Pharma	-0.79%	-2.85%	-16.09%	+9.70%	+223.11%
PHAR Pharming Group	-1.24%	-4.22%	-17.13%	-31.24%	-35.46%
PRQR ProQR Therapeutics	-3.68%	-3.68%	-23.41%	-9.25%	-33.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTH Sensei Biotherapeutics	2.93	Moderate Buy	$56.25	119.64% Upside
NVCT Nuvectis Pharma	2.80	Moderate Buy	$36.25	80.08% Upside
PHAR Pharming Group	2.20	Hold	$38.67	305.74% Upside
PRQR ProQR Therapeutics	2.63	Moderate Buy	$7.60	384.08% Upside

Current Analyst Ratings Breakdown

Latest PRQR, FTH, NVCT, and PHAR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/1/2026	PRQR ProQR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
10/1/2026	PRQR ProQR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$3.00
10/1/2026	PRQR ProQR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$8.00
9/24/2026	NVCT Nuvectis Pharma	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$39.00
9/23/2026	PHAR Pharming Group	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$38.00
9/22/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00
9/21/2026	NVCT Nuvectis Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$70.00
9/15/2026	FTH Sensei Biotherapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
9/14/2026	FTH Sensei Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/14/2026	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$37.00

(Data available from 10/9/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$14.74 per share	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	$0.72 per share	N/A
PHAR Pharming Group	$376.13M	1.79	$0.20 per share	48.12	$3.95 per share	2.41
PRQR ProQR Therapeutics	$18.36M	9.01	N/A	N/A	$0.53 per share	2.96

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
NVCT Nuvectis Pharma	-$26.44M	-$1.31	N/A	N/A	N/A	N/A	-184.25%	-105.24%	11/3/2026 (Estimated)
PHAR Pharming Group	$2.85M	$0.12	79.42	35.30	N/A	2.51%	3.40%	1.90%	11/5/2026 (Estimated)
PRQR ProQR Therapeutics	-$47.73M	-$0.46	N/A	N/A	N/A	-223.51%	-73.83%	-35.14%	11/5/2026 (Estimated)

Latest PRQR, FTH, NVCT, and PHAR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	PHAR Pharming Group	$0.12	N/A	N/A	N/A	$103.54 million	N/A
11/5/2026	Q3 2026	PRQR ProQR Therapeutics	-$0.11	N/A	N/A	N/A	$4.30 million	N/A
11/3/2026	Q3 2026	NVCT Nuvectis Pharma	-$0.22	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	PRQR ProQR Therapeutics	-$0.1303	-$0.0914	+$0.0389	-$0.09	$4.56 million	$10.00 million
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A
8/4/2026	Q2 2026	NVCT Nuvectis Pharma	-$0.2620	-$0.30	-$0.0380	-$0.30	N/A	N/A
7/30/2026	Q2 2026	PHAR Pharming Group	$0.0630	$0.02	-$0.0430	$0.02	$99.52 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NVCT Nuvectis Pharma	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
PRQR ProQR Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTH Sensei Biotherapeutics	N/A	19.69	19.69
NVCT Nuvectis Pharma	N/A	1.68	1.68
PHAR Pharming Group	0.34	3.01	2.31
PRQR ProQR Therapeutics	N/A	3.49	3.49

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTH Sensei Biotherapeutics	10.50%
NVCT Nuvectis Pharma	96.77%
PHAR Pharming Group	0.03%
PRQR ProQR Therapeutics	32.65%

Insider Ownership

Company	Insider Ownership
FTH Sensei Biotherapeutics	7.00%
NVCT Nuvectis Pharma	28.55%
PHAR Pharming Group	2.07%
PRQR ProQR Therapeutics	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTH Sensei Biotherapeutics	29	25.84 million	24.03 million	Not Optionable
NVCT Nuvectis Pharma	13	32.64 million	23.32 million	Not Optionable
PHAR Pharming Group	407	70.78 million	69.31 million	Not Optionable
PRQR ProQR Therapeutics	166	105.36 million	96.51 million	Optionable

PRQR, FTH, NVCT, and PHAR Headlines

Recent News About These Companies

HC Wainwright Has Negative Estimate for PRQR FY2028 Earnings

October 5, 2026 | americanbankingnews.com

FY2028 Earnings Estimate for PRQR Issued By HC Wainwright

October 5, 2026 | marketbeat.com

Beam Therapeutics (NASDAQ:BEAM) and ProQR Therapeutics (NASDAQ:PRQR) Critical Contrast

October 4, 2026 | americanbankingnews.com

Chardan Capital Reaffirms "Buy" Rating for ProQR Therapeutics (NASDAQ:PRQR)

October 3, 2026 | americanbankingnews.com

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Target Cut by HC Wainwright

October 3, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: ProQR (PRQR) and Sagimet Biosciences, Inc. Class A (SGMT)

October 2, 2026 | theglobeandmail.com

ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease

October 2, 2026 | marketbeat.com

ProQR Therapeutics' (PRQR) "Buy" Rating Reiterated at Chardan Capital

October 1, 2026 | marketbeat.com

ProQR Therapeutics (NASDAQ:PRQR) Stock Price Target Lowered at HC Wainwright

October 1, 2026 | marketbeat.com

ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor

September 23, 2026 | globenewswire.com

ProQR Therapeutics N.V. (NASDAQ:PRQR) Receives Average Rating of "Moderate Buy" from Brokerages

September 23, 2026 | marketbeat.com

ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment

September 10, 2026 | finance.yahoo.com

ProQR Announces First Participant Dosed in Phase 1 Study of AX-0811 and Virtual Investor and Analyst Educational Event on September 30, 2026

September 9, 2026 | globenewswire.com

ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving Average - Should You Sell?

September 9, 2026 | marketbeat.com

ProQR to Participate in Upcoming Investor Conferences in September 2026

September 2, 2026 | globenewswire.com

ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts

August 21, 2026 | seekingalpha.com

ProQR Reports Higher Revenue but Ongoing Losses in Second Quarter 2026 Results

August 15, 2026 | theglobeandmail.com

ProQR posts Q2 2026 results as Axiomer RNA editing gains first clinical validation

August 15, 2026 | theglobeandmail.com

ProQR Therapeutics Reports First Clinical Validation of Axiomer RNA Editing Platform, Positive AX-0810 Data and Upcoming Pipeline Milestones

August 13, 2026 | quiverquant.comQ

ProQR Announces Second Quarter 2026 Operating and Financial Results

August 13, 2026 | globenewswire.com

Bart Filius Purchases 150,000 Shares of ProQR Therapeutics (NASDAQ:PRQR) Stock

July 29, 2026 | insidertrades.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR, FTH, NVCT, and PHAR Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

$25.61 +0.69 (+2.77%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$25.61 0.00 (0.00%)

As of 09:21 AM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Nuvectis Pharma NASDAQ:NVCT

$20.13 -0.16 (-0.79%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$20.12 -0.01 (-0.05%)

As of 10/8/2026 07:30 PM Eastern

Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma. It is also developing NXP900, a small molecule drug candidate, which is in Phase 1a clinical trails that inhibits the Proto-oncogene c-Src and YES1 kinases. It has license agreement with the CRT Pioneer Fund for the NXP800 and any of related derivatives; and the University of Edinburgh for the NXP900 and any of associated derivatives. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.

Pharming Group NASDAQ:PHAR

$9.53 -0.12 (-1.24%)

Closing price 10/8/2026 03:57 PM Eastern

Extended Trading

$9.46 -0.07 (-0.73%)

As of 04:03 AM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

ProQR Therapeutics NASDAQ:PRQR

$1.57 -0.06 (-3.68%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$1.59 +0.02 (+1.27%)

As of 09:12 AM Eastern

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1). It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for nonalcoholic steatohepatitis (NASH); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as various other targets. In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system. The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRQR, FTH, NVCT, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRQR, FTH, NVCT, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRQR, FTH, NVCT, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR, FTH, NVCT, and PHAR Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

Nuvectis Pharma NASDAQ:NVCT

Pharming Group NASDAQ:PHAR

ProQR Therapeutics NASDAQ:PRQR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRQR, FTH, NVCT, and PHAR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRQR, FTH, NVCT, and PHAR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRQR, FTH, NVCT, and PHAR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR, FTH, NVCT, and PHAR Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

Nuvectis Pharma NASDAQ:NVCT

Pharming Group NASDAQ:PHAR

ProQR Therapeutics NASDAQ:PRQR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools